Pragmatic Institute’s New Course Advances Product Management and Design Collaboration
Pragmatic Institute’s New Course Advances Product Management and Design Collaboration
Pragmatic Institute a trusted enterprise education partner and global authority on product management, product marketing, data science and design has launched a new course,
Design, for product managers who want to leverage the power of design in product development. In this course, product managers learn how to reduce friction with their design teams, elevate communication and collaboration, and inspire innovation to create intuitive products that solve market problems and exceed user expectations. By gaining the understanding and techniques to enhance cross-functional collaboration, product teams will be able to create solutions that are embraced by the market.
Lodasoft Names Mark Ramirez New Head of Product
Lodasoft Names Mark Ramirez New Head of Product
Lodasoft, a Digital Workflow Platform designed by mortgage veterans to revolutionize loan origination and task automation, today announced that Mark Ramirez has joined the company as Head of Product. In his role, Ramirez will leverage his entrepreneurial thinking, his vast experience of the market and his deep understanding of the mortgage industry to further innovate Lodasofts product portfolio. Bringing more than 25 years of experience in the mortgage banking industry, Ramirez was previously the Director of Software Engineering for loanDepot, where he led and managed the team that built and maintained loanDepot’s proprietary product & pricing engine. Additionally, he was the solution architect for the team that successfully launched loanDepots melloClear, expanding on the mello smartloan„¢ automation suite.
INSU Acquisition Corp. III Announces Pricing of Upsized $218,000,000 Initial Public Offering
INSU Acquisition Corp. III Announces Pricing of Upsized $218,000,000 Initial Public Offering
PHILADELPHIA, PA, Dec. 17, 2020 INSU Acquisition Corp. III (NASDAQ:IIIIU) (the “Company”), a blank-check company sponsored by Cohen & Company (NYSE American: COHN) and formed for the purpose of acquiring or merging with one or more businesses or entities in the insurance industry, today announced the pricing of its upsized initial public offering of 21,800,000 units at a price of $10.00 per unit, for gross proceeds to the Company of $218,000,000. The Company’s units will be listed on the Nasdaq Capital Market under the symbol “IIIIU” and will begin trading on December 18, 2020. Each unit issued in the offering consists of one share of the Company’s Class A common stock and one-third of one warrant, each whole warrant exercisable for one share of Class A common stock at an exercise pric
Progress CEO Yogesh Gupta Elected Co-Chair of MassTLC Board of Trustees
BEDFORD, Mass., Dec. 09, 2020
Progress (NASDAQ: PRGS), the leading provider of products to develop, deploy and manage high-impact business applications, today announced that CEO Yogesh Gupta has been named Co-Chair of the
MassTLC Board of Trustees. Gupta will serve a two-year term initially alongside Vecna Technologies Co-Founder and current MassTLC Co-Chair Debbie Theobald, whose term ends in 2021.
Gupta was elected to the MassTLC Board of Trustees in 2019. In this role, and as a member of the Executive Diversity and Inclusion Steering Committee (EDISC), he was one of the architects of the Council’s 2030 Challenge to double the percentage of Black and Latinx workers in tech over the coming decade, and framer of the recently formed
News Category Global Banking & Finance Reviews
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the closing of its previously announced initial public offering of 13,225,000 shares of its common stock, which includes 1,725,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $21.00 per share. Including the option exercise, the aggregate gross